Villmones, Heidi Cecilie
Haug, Erik Skaaheim
Ulvestad, Elling
Grude, Nils
Stenstad, Tore
Halland, Adrian
Kommedal, Øyvind
Article History
Received: 28 November 2017
Accepted: 6 March 2018
First Online: 16 March 2018
Competing Interests
: ØK has contributed to the development of the RipSeq NGS software and is a minor shareholder in Pathogenomix. The remaining authors declare no competing financial interests.